采用CLSI M27 - A3肉汤微量稀释法对新生隐球菌-格特隐球菌复合种的异氟康唑MIC分布及流行病学截断值进行多中心研究。
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.
作者信息
Espinel-Ingroff A, Chowdhary A, Gonzalez G M, Guinea J, Hagen F, Meis J F, Thompson G R, Turnidge J
机构信息
VCU Medical Center, Richmond, Virginia, USA
Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.
出版信息
Antimicrob Agents Chemother. 2015 Jan;59(1):666-8. doi: 10.1128/AAC.04055-14. Epub 2014 Oct 13.
Abstract
Epidemiological cutoff values (ECVs) of isavuconazole are not available for Cryptococcus spp. The isavuconazole ECVs based on wild-type (WT) MIC distributions for 438 Cryptococcus neoformans nongenotyped isolates, 870 isolates of genotype VNI, and 406 Cryptococcus gattii isolates from six laboratories and different geographical areas were 0.06, 0.12, and 0.25 μg/ml, respectively. These ECVs may aid in detecting non-WT isolates with reduced susceptibilities to isavuconazole.
摘要
对于隐球菌属，目前尚无艾沙康唑的流行病学临界值（ECV）。基于来自六个实验室和不同地理区域的438株非基因分型新生隐球菌分离株、870株VNI基因型分离株以及406株加氏隐球菌分离株的野生型（WT）最低抑菌浓度（MIC）分布，艾沙康唑的ECV分别为0.06、0.12和0.25μg/ml。这些ECV可能有助于检测对艾沙康唑敏感性降低的非WT分离株。
相似文献
1
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.采用CLSI M27 - A3肉汤微量稀释法对新生隐球菌-格特隐球菌复合种的异氟康唑MIC分布及流行病学截断值进行多中心研究。
Antimicrob Agents Chemother. 2015 Jan;59(1):666-8. doi: 10.1128/AAC.04055-14. Epub 2014 Oct 13.
2
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.新型隐球菌-格特隐球菌种复合体：氟康唑、伊曲康唑、泊沙康唑和伏立康唑野生型药敏终点分布和流行病学折点的国际研究。
Antimicrob Agents Chemother. 2012 Nov;56(11):5898-906. doi: 10.1128/AAC.01115-12. Epub 2012 Sep 4.
3
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.新型隐球菌-格特隐球菌种复合体：两性霉素 B 和氟胞嘧啶野生型药敏终点分布及流行病学折点的国际研究。
Antimicrob Agents Chemother. 2012 Jun;56(6):3107-13. doi: 10.1128/AAC.06252-11. Epub 2012 Mar 5.
4
Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.巴西亚马逊地区新型隐球菌 VNI 和格特隐球菌 VGII 的 Etest、Vitek 2 和临床与实验室标准协会微量肉汤稀释法比较抗真菌药敏分析。
Med Mycol. 2019 Oct 1;57(7):864-873. doi: 10.1093/mmy/myy150.
5
Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.对来自丹麦的108株新型隐球菌复合体和格特隐球菌复合体临床分离株进行的分子流行病学及体外抗真菌药敏试验
Mycoses. 2016 Sep;59(9):576-84. doi: 10.1111/myc.12507. Epub 2016 Apr 8.
6
Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.评估Etest法测定伊曲康唑对加氏隐球菌和新生隐球菌的最低抑菌浓度。
Antimicrob Agents Chemother. 2008 Aug;52(8):2959-61. doi: 10.1128/AAC.00646-08. Epub 2008 Jun 16.
7
In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.采用美国临床和实验室标准协会（CLSI）方法及流式细胞术对新型隐球菌格鲁比变种AFLP1/VNI和加蒂隐球菌AFLP6/VGII进行两性霉素B的体外药敏试验。
Mycoses. 2015 May;58(5):273-9. doi: 10.1111/myc.12310. Epub 2015 Mar 10.
8
Molecular epidemiology and antifungal susceptibility profiles of clinical species complex.临床 种复合体的分子流行病学和抗真菌药敏谱。
J Med Microbiol. 2020 Jan;69(1):72-81. doi: 10.1099/jmm.0.001101.
9
Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex.新型隐球菌/格特隐球菌种复合体中抗真菌药敏性与分子型的相关性。
Med Mycol. 2012 Apr;50(3):328-32. doi: 10.3109/13693786.2011.602126. Epub 2011 Aug 23.
10
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.多中心研究伊曲康唑 MIC 分布和曲霉属的 CLSI M38-A2 肉汤微量稀释法的流行病学截断值。
Antimicrob Agents Chemother. 2013 Aug;57(8):3823-8. doi: 10.1128/AAC.00636-13. Epub 2013 May 28.
引用本文的文献
1
Clinical and Molecular Characterization of Feline Sporotrichosis in the Brazilian Amazon: PCR-Based Identification of .巴西亚马逊地区猫孢子丝菌病的临床和分子特征：基于PCR的鉴定……
Animals (Basel). 2025 Aug 7;15(15):2318. doi: 10.3390/ani15152318.
2
Efficacy and safety of isavuconazole versus voriconazole for the treatment of invasive fungal infections: a meta-analysis with trial sequential analysis.艾沙康唑与伏立康唑治疗侵袭性真菌感染的疗效与安全性：一项采用序贯试验分析的荟萃分析
BMC Infect Dis. 2025 Feb 18;25(1):230. doi: 10.1186/s12879-025-10627-w.
3
Cryptococcosis-a systematic review to inform the World Health Organization Fungal Priority Pathogens List.隐球菌病——为世界卫生组织真菌优先病原体清单提供信息的系统评价。
Med Mycol. 2024 Jun 27;62(6). doi: 10.1093/mmy/myae043.
4
Exposure of to Seven Commonly Used Agricultural Azole Fungicides Induces Resistance to Fluconazole as Well as Cross-Resistance to Voriconazole, Posaconazole, Itraconazole and Isavuconazole.暴露于七种常用的农用唑类杀菌剂会诱导对氟康唑产生抗性，以及对伏立康唑、泊沙康唑、伊曲康唑和艾沙康唑产生交叉抗性。
Pathogens. 2023 Apr 29;12(5):662. doi: 10.3390/pathogens12050662.
5
False-negative cerebral spinal fluid cryptococcal antigen lateral flow assay due to postzone phenomenon in a patient with disseminated cryptococcal disease: a case report.假阴性脑脊髓液隐球菌抗原侧向流动检测由于播散性隐球菌病患者的后带现象：病例报告。
J Int Med Res. 2023 Mar;51(3):3000605231156767. doi: 10.1177/03000605231156767.
6
New Perspectives on Antimicrobial Agents: Isavuconazole.抗微生物药物的新视角：伊曲康唑。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0017722. doi: 10.1128/aac.00177-22. Epub 2022 Aug 15.
7
Pharmacokinetics of isavuconazole in healthy cats after oral and intravenous administration.伊曲康唑在健康猫体内经口服和静脉注射后的药代动力学。
J Vet Intern Med. 2022 Jul;36(4):1422-1429. doi: 10.1111/jvim.16452. Epub 2022 May 26.
8
Prevalence, Genetic Structure, and Antifungal Susceptibility of the Species Complex Strains Collected from the Arboreal Niche in Poland.从波兰树栖生态位收集的物种复合菌株的患病率、遗传结构和抗真菌药敏性
Pathogens. 2021 Dec 22;11(1):8. doi: 10.3390/pathogens11010008.
9
Risk Factors for Cryptococcal Meningitis Recurrence in Human Immunodeficiency Virus (HIV)-Infected Patients in a Large Chinese Acquired Immune Deficiency Syndrome (AIDS) Treatment Center.在中国大型艾滋病治疗中心，感染人类免疫缺陷病毒（HIV）的患者中，隐球菌性脑膜炎复发的危险因素。
Med Sci Monit. 2021 Dec 15;27:e933688. doi: 10.12659/MSM.933688.
10
Antifungal Susceptibility Profiles of var. and Clinical Isolates in Guangxi, Southern China.中国南方广西地区[具体菌株名称]变种及临床分离株的抗真菌药敏谱
Front Microbiol. 2021 Aug 10;12:708280. doi: 10.3389/fmicb.2021.708280. eCollection 2021.
本文引用的文献
1
Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.对八种念珠菌属对氟康唑、泊沙康唑和伏立康唑耐药性检测的流行病学截断值的多实验室研究。
Antimicrob Agents Chemother. 2014;58(4):2006-12. doi: 10.1128/AAC.02615-13. Epub 2014 Jan 13.
2
In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.体外研究伊曲康唑和其他抗真菌药物对全球机会性酵母菌和霉菌的活性。
J Clin Microbiol. 2013 Aug;51(8):2608-16. doi: 10.1128/JCM.00863-13. Epub 2013 Jun 5.
3
Autochthonous and dormant Cryptococcus gattii infections in Europe.欧洲本土和休眠的新型隐球菌感染。
Emerg Infect Dis. 2012 Oct;18(10):1618-24. doi: 10.3201/eid1810.120068.
4
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.新型隐球菌-格特隐球菌种复合体：氟康唑、伊曲康唑、泊沙康唑和伏立康唑野生型药敏终点分布和流行病学折点的国际研究。
Antimicrob Agents Chemother. 2012 Nov;56(11):5898-906. doi: 10.1128/AAC.01115-12. Epub 2012 Sep 4.
5
Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population.荷兰临床新型隐球菌群体内广泛的遗传多样性。
J Clin Microbiol. 2012 Jun;50(6):1918-26. doi: 10.1128/JCM.06750-11. Epub 2012 Mar 21.
6
Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen.美国的荚膜组织胞浆菌：一种新兴病原体感染的临床特征。
Clin Infect Dis. 2011 Dec;53(12):1188-95. doi: 10.1093/cid/cir723. Epub 2011 Oct 19.
7
A diverse population of Cryptococcus gattii molecular type VGIII in southern Californian HIV/AIDS patients.加利福尼亚南部 HIV/AIDS 患者中存在多种 VGIII 型荚膜组织胞浆菌。
PLoS Pathog. 2011 Sep;7(9):e1002205. doi: 10.1371/journal.ppat.1002205. Epub 2011 Sep 1.
8
In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.来自印度西北部的 308 株新型隐球菌和格特隐球菌 B 型临床和环境分离株的体外抗真菌药敏谱和基因型。
J Med Microbiol. 2011 Jul;60(Pt 7):961-967. doi: 10.1099/jmm.0.029025-0. Epub 2011 Mar 10.
9
In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates.对全球范围内 350 株临床、兽医和环境分离的隐球菌的体外抗真菌药敏试验和扩增片段长度多态性基因分型研究。
Antimicrob Agents Chemother. 2010 Dec;54(12):5139-45. doi: 10.1128/AAC.00746-10. Epub 2010 Sep 20.
10
Mixed infections and In Vivo evolution in the human fungal pathogen Cryptococcus neoformans.新型隐球菌中人真菌病原体的混合感染和体内进化。
mBio. 2010 May 18;1(1):e00091-10. doi: 10.1128/mBio.00091-10.
Zotero 插件